Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;11(Suppl 17):S2173-S2180.
doi: 10.21037/jtd.2019.10.40.

COPD and the gut-lung axis: the therapeutic potential of fibre

Affiliations
Review

COPD and the gut-lung axis: the therapeutic potential of fibre

Annalicia Vaughan et al. J Thorac Dis. 2019 Oct.

Abstract

Current management strategies for chronic obstructive pulmonary disease (COPD) incorporate a step-wise, multidisciplinary approach to effectively manage patient symptoms and prevent disease progression. However, there has been limited advancement in therapies to address the underlying cause of COPD pathogenesis. Recent research has established the link between the lungs and the gut-the gut-lung axis -and the gut microbiome is a major component. The gut microbiome is likely perturbed in COPD, contributing to chronic inflammation. Diet is a readily modifiable factor and the diet of COPD patients is often deficient in nutrients such as fibre. The metabolism of dietary fibre by gut microbiomes produces anti-inflammatory short chain fatty acid (SCFAs), which could protect against inflammation in the lungs. By addressing the 'fibre gap' in the diet of COPD patients, this targeted dietary intervention may reduce inflammation, both systemically and in the airways, and value-add to the paradigm shift in respiratory medicine, from reactive to personalised and participatory medicine.

Keywords: Chronic obstructive pulmonary disease (COPD); metagenomics; microbiome.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017;207:436-42. 10.5694/mja17.00686 - DOI - PubMed
    1. Jones B, Donovan C, Liu G, et al. Animal models of COPD: What do they tell us? Respirology 2017;22:21-32. 10.1111/resp.12908 - DOI - PubMed
    1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96. 10.1016/S0140-6736(12)61729-2 - DOI - PMC - PubMed
    1. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016;21:14-23. 10.1111/resp.12660 - DOI - PubMed
    1. Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol 2012;5:7. 10.1038/mi.2011.55 - DOI - PMC - PubMed